- Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test (PST), showed 98% response rate over 105 clinical S. aureus strains
Lyon (France) et Cambridge (MA, US), October 9, 2023 at 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced a very high spectrum of activity of its anti-S. aureus (PP1493 and PP1815) phages against clinical bacterial strains.
A retrospective analysis was carried out with 105 clinical Staphylococcus aureus strains which were tested using PHAXIAM’s phagogram in the context of clinical trials, salvage therapy and early access program (AAC). The results demonstrated that 98% of these pathogenic S. aureus strains were susceptible to at least one of the two PHAXIAM’s anti-S. aureus phages (PP1493 and PP1815).
Phagogram is an in vitro diagnostic (IVD) test designed to determine the in-vitro activity of PHAXIAM’s phages to patients’ bacterial strains. Phagogram is the first CE-marked IVD test dedicated to phage activity evaluation.
Thibaut du Fayet, Chief Executive Officer of PHAXIAM Therapeutics, stated: “The data obtained from this retrospective analysis confirm that our phagogram solution is a very efficient IVD platform in our current and upcoming clinical developments. The 98% spectrum of activity of our anti-S. aureus phages is exceptionally high when compared with other competing solutions. The data achieved also prove that our phagogram performs very well, making it a unique asset for the development of other phages in our portfolio. I want to thank all our teams for the outstanding work on this project over several years. Such a differentiating asset, coupled with our unique set of clinical activity data from our compassionate and AAC treatments, confirm that PHAXIAM is well positioned to become a global leader in phage therapy and strengthen the fight against severe and resistant infections.”
Full PR available here